Prevalence of Neutralizing Antibodies to AAV2 and AAV9 in Individuals with Niemann-Pick Disease, Type C1
- 1 April 2025
- journal article
- Published by SAGE Publications in Human Gene Therapy
- Vol. 36 (7-8) , 729-737
Abstract
Niemann-Pick disease, type C1 (NPC1), is a rare, fatal neurodegenerative disorder caused by pathological variations in NPC1. We and others have previously demonstrated the efficacy of systemic adeno-associated virus (AAV) gene therapy with AAV9 in murine models of NPC1. The presence of neutralizing antibodies (NAbs) caused by natural exposure to wildtype AAVs may impair AAV transduction efficacy and reduce or negate the benefit of gene therapy. In addition, there remains the question of whether individuals seroconvert with age and whether seroconversion limits the window of therapeutic efficacy. Thus, we assessed the prevalence of anti-AAV9 and anti-AAV2 NAbs in serum samples from 22 individuals with NPC1 at two different time points: one closer to diagnosis (0.9-17 years old) and another collected between 4 and 15 years later during follow-up (6-28 years old). At a titer of <1:5, we found that more than half of the cohort lacked NAbs against either AAV2 (68.2%) or AAV9 (59.1% at time 1, 63.6% at time 2). Notably, only 3 out of 22 individuals showed a transition from undetectable to detectable NAb titers, and most participants maintained stable titers over time, unaffected by age. These data support the feasibility of systemic or direct CNS AAV9 gene therapy in this patient population.Keywords
This publication has 64 references indexed in Scilit:
- Efficacy and safety of arimoclomol in Niemann‐Pick disease type C: Results from a double‐blind, randomised, placebo‐controlled, multinational phase 2/3 trial of a novel treatmentJournal of Inherited Metabolic Disease, 2021
- Association of Miglustat With Swallowing Outcomes in Niemann-Pick Disease, Type C1JAMA Neurology, 2020
- Long‐term survival outcomes of patients with Niemann‐Pick disease type C receiving miglustat treatment: A large retrospective observational studyJournal of Inherited Metabolic Disease, 2020
- Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patientsCellular Immunology, 2019
- Health outcomes in spinal muscular atrophy type 1 following AVXS‐101 gene replacement therapyPediatric Pulmonology, 2018
- Pulmonary involvement in Niemann-Pick C type 1European Journal of Pediatrics, 2018
- Methods for Gene Transfer to the Central Nervous System2014
- The prevalence of neutralizing antibodies against adeno‐associated virus capsids is reduced in young Japanese individualsJournal of Medical Virology, 2013
- Niemann–Pick diseases2013
- Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)Journal of Medical Virology, 1999